# Vertex Pharmaceuticals acquisition of Crinetics

> Live situation record from CLSTR: https://clstr.news/situations/vertex-pharmaceuticals-acquisition-of-crinetics
> Updated: 2026-08-03T20:05:55.000Z. Sources: 2. Developments: 2.

In early July 2026, Vertex Pharmaceuticals announced a $10 billion deal to acquire Crinetics, signaling a major expansion of its drug pipeline. By early August, Vertex reported a stronger-than-expected second‑quarter performance, driven by robust sales of its cystic fibrosis therapies Alyftrek and Trikafta. The company raised the upper end of its annual revenue forecast to $13.1‑$13.2 billion, explicitly noting that the outlook excludes the pending Crinetics acquisition, which is expected to close in the third quarter.

The sequence shows Vertex moving from the strategic announcement of a large acquisition to leveraging its existing CF drug portfolio to boost earnings, while awaiting the completion of the Crinetics deal.

## Timeline

### 2026-08-03: Vertex Pharmaceuticals lifts revenue outlook on strong cystic fibrosis drug sales

Vertex raised its annual revenue target to $13.1‑$13.2 bn, driven by strong cystic fibrosis drug sales, while pending a $10 bn Crinetics acquisition.

2 sources. https://clstr.news/cluster/vertex-pharmaceuticals-lifts-revenue-outlook-on-strong-cystic-fibrosis-drug-sales

### 2026-07-06: Vertex Pharmaceuticals to acquire Crinetics for $10 billion

Vertex Pharma agreed to buy Crinetics for about $10 billion ($85 per share), adding endocrine drugs PALSONIFY and atumelnant, with the deal slated to close in Q3 2026; Crinetics stock jumped ~100% as Vertex’s t

10 sources. https://clstr.news/cluster/vertex-pharmaceuticals-to-buy-crinetics-in-10-billion-deal

---
Cite as: Vertex Pharmaceuticals acquisition of Crinetics. CLSTR, https://clstr.news/situations/vertex-pharmaceuticals-acquisition-of-crinetics